Similar tendencies were found by Goldstone and colleagues (2016), but correlations between GLP-1 levels and anticipatory food reward responses failed to reach significance (Goldstone et al., 2016)
Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities
Wegovy, another FDA-approved weight management medication , functions by mimicking a hormone in the intestines known as GLP-1, which triggers feelings of fullness, thereby helping to reduce appetite and calorie intake
Due to their effects on appetite and gastric transit, medications that manipulate the incretin response began gathering interest as potential pharmacological options in the treatment of obesity
Many other weight loss programs that prescribe GLP-1 medications work within certain BMI limitations
Patients should maintain open communication with their healthcare team about ongoing symptoms, as adjustments to dosing or timing might be necessary for optimal management
